NASDAQ:ZBIO Zenas BioPharma Q1 2025 Earnings Results & Report $27.93 -0.08 (-0.29%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$27.94 +0.02 (+0.05%) As of 11/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zenas BioPharma beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.80 versus the -$1.15 consensus estimate, while revenue of $10 million topped the $5 million estimate by $5 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 15, 2025TimeBefore Market OpensConference Call7:00 AM ET Zenas BioPharma EPS ResultsActual EPS-$0.80Consensus EPS -$1.15Beat/MissBeat by +$0.35One Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersZenas BioPharma Revenue ResultsActual Revenue$10 millionExpected Revenue$5 millionBeat/MissBeat by +$5.00 millionYoY Revenue GrowthN/AUpcoming EarningsZenas BioPharma's Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zenas BioPharma Q1 2025 Earnings FAQ Did Zenas BioPharma beat earnings estimates for Q1 2025? Zenas BioPharma (NASDAQ:ZBIO) reported earnings of -$0.80 per share for Q1 2025, beating the consensus estimate of -$1.15. The report was announced on Thursday, May 15, 2025. What was Zenas BioPharma's revenue for Q1 2025? Zenas BioPharma reported revenue of $10 million for Q1 2025, against a consensus estimate of $5 million. When is Zenas BioPharma's next earnings date? Zenas BioPharma's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zenas BioPharma on the company's earnings history page. Zenas BioPharma Earnings HeadlinesFY2026 EPS Forecast for Zenas BioPharma Decreased by AnalystNovember 13, 2026 | americanbankingnews.comZenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on WednesdayNovember 11, 2026 | americanbankingnews.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading. | Traders Agency (Ad)Zenas BioPharma to Present at the Jefferies London Global Healthcare ConferenceNovember 9, 2026 | finance.yahoo.comZenas BioPharma Launches New $200 Million Stock OfferingNovember 6, 2026 | tipranks.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Stock Has Average Price Target of $46.71November 6, 2026 | americanbankingnews.comSee More Zenas BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email. Email Address About Zenas BioPharmaZenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business.Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.The company is led by co-founder and Chief Executive Officer Hua Mu, who has experience in the biopharmaceutical industry. Zenas’s development efforts are aimed at patients with immune-mediated diseases for which existing treatment options may be limited.View Zenas BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.